Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 360,947,968
  • Shares Outstanding, K 2,632,543
  • Annual Sales, $ 82,059 M
  • Annual Income, $ 15,119 M
  • 60-Month Beta 0.68
  • Price/Sales 4.40
  • Price/Cash Flow 11.91
  • Price/Book 5.60
Trade JNJ with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.82
  • Number of Estimates 6
  • High Estimate 1.86
  • Low Estimate 1.78
  • Prior Year 1.88
  • Growth Rate Est. (year over year) -3.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.65 +2.59%
on 10/30/20
153.14 -10.47%
on 10/12/20
-11.77 (-7.91%)
since 09/30/20
3-Month
133.65 +2.59%
on 10/30/20
155.47 -11.81%
on 09/03/20
-9.73 (-6.63%)
since 07/30/20
52-Week
109.16 +25.60%
on 03/23/20
157.00 -12.67%
on 04/23/20
+4.27 (+3.21%)
since 10/30/19

Most Recent Stories

More News
Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance

Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.

JNJ : 137.11 (-0.06%)
ALKS : 16.25 (-0.18%)
EBS : 89.97 (-0.88%)
VCEL : 18.53 (-1.59%)
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study

Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results

JNJ : 137.11 (-0.06%)
SNY : 45.30 (-0.46%)
AZN : 50.16 (-1.78%)
PFE : 35.48 (+0.57%)
MRK : 75.21 (-0.90%)
LLY : 130.46 (-1.58%)
NVS : 78.08 (+0.01%)
3 Stocks Set to Soar from the Second Wave of Covid-19

With daily coronavirus cases crossing 87,000 in the United States, the second wave is already making its presence felt. Companies like Johnson & Johnson (JNJ), Abbott (ABT), and Teladoc (TDOC) have been...

JNJ : 137.11 (-0.06%)
ABT : 105.11 (+0.10%)
TDOC : 196.46 (-9.84%)
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance

AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.

JNJ : 137.11 (-0.06%)
RHHBY : 39.9900 (-0.52%)
AMGN : 216.94 (-0.40%)
ABBV : 85.10 (+5.49%)
4 Stocks HIKING Dividends to Buy for November       

Investors looking for dividend stocks to secure a steady income amid heightened market volatility should bet on Johnson & Johnson (JNJ), The Coca Cola Company (KO), McDonald’s (MCD), and Target (TGT)....

TGT : 152.22 (-1.32%)
JNJ : 137.11 (-0.06%)
KO : 48.06 (+0.08%)
MCD : 213.00 (-0.91%)
Glaxo (GSK) Q3 Earnings Top, Vaccines Segment on Recovery Path

Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.

JNJ : 137.11 (-0.06%)
PFE : 35.48 (+0.57%)
GSK : 33.42 (-1.59%)
VIR : 31.44 (-7.06%)
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q3 Earnings?

AbbVie's (ABBV) Q3 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.

JNJ : 137.11 (-0.06%)
RHHBY : 39.9900 (-0.52%)
HZNP : 74.93 (-3.59%)
ABBV : 85.10 (+5.49%)
Thinking about trading options or stock in Microsoft, First Solar, Zoom Video, Amazon, or Johnson & Johnson?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSFT, FSLR, ZM, AMZN, and JNJ.

JNJ : 137.11 (-0.06%)
Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More

Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.

JNJ : 137.11 (-0.06%)
GILD : 58.15 (-0.65%)
UTHR : 134.23 (+3.06%)
GSK : 33.42 (-1.59%)
AMGN : 216.94 (-0.40%)
Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss

Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.

JNJ : 137.11 (-0.06%)
RHHBY : 39.9900 (-0.52%)
NVS : 78.08 (+0.01%)
ABBV : 85.10 (+5.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 139.99
1st Resistance Point 138.55
Last Price 137.11
1st Support Level 134.66
2nd Support Level 132.21

See More

52-Week High 157.00
Fibonacci 61.8% 138.73
Last Price 137.11
Fibonacci 50% 133.08
Fibonacci 38.2% 127.43
52-Week Low 109.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar